ABVC BioPharma Receives Additional $100,000 Payment from OncoX, Advancing Oncology Licensing Strategy

ABVC BioPharma has received an additional $100,000 licensing payment from OncoX BioPharma, bringing total payments to $695,950 under their existing agreement. This marks the fifth licensing payment made by OncoX in 2025, further advancing ABVC's multi-partner licensing strategy and oncology revenue framework. The continued payments reflect progress in the partnership and demonstrate ABVC's transition toward an asset-light, cash-visible international licensing platform with scalable returns.

OncoX BioPharma specializes in developing plant-derived oncology therapeutics, with its lead candidate derived from Grifola frondosa (maitake mushroom) extract showing potential in treating triple-negative breast cancer, non-small-cell lung cancer, pancreatic cancer and myelodysplastic syndrome. The company collaborates with several leading Japanese biomedical companies and academic institutions to co-develop Precision Gene-Oriented Therapies and Anti-Fibrosis Technologies, combining stem-cell and immunotherapy platforms to accelerate clinical validation and expand global applications.

ABVC's three-tier value-amplification model demonstrates the financial structure of these partnerships. In the short-term (0-12 months), licensing payments totaling $695,950 received to date provide cash-flow visibility and consistent milestone execution. Long-term (24+ months), the company stands to receive 5% royalty on net sales up to cumulative $55 million, creating sustainable, high-profit-margin recurring income. Based on consolidated data across all licensing partners, ABVC's total contractual cash revenue pool has the potential to reach up to $14.25 million, with $2.14 million received as of October 2025.

Dr. Uttam Patil, ABVC's Chief Executive Officer, emphasized that the continued licensing payments reflect the progress and execution of the partnership strategy. The collaboration illustrates the effectiveness of ABVC's licensing-driven business model in transforming research and development assets into recurring value creation. OncoX operates under a strategic collaboration and manufacturing framework with BioKey Inc., a U.S. FDA-registered facility, and seeks to expand its global footprint with development and commercialization plans in the United States, Japan, Taiwan, and other key Asia-Pacific markets.

The partnership represents a growing biotechnology network connecting U.S. and Asian markets, with OncoX preparing for future clinical milestones and pursuing long-term international partnerships. According to market research from Allied Market Research, cross-sector applications in preventative medicine, chronic disease care, aesthetic medicine, and animal health are projected to reach a global market size of $187 million by 2030. This expansion into adjacent fields complements the core oncology focus and creates additional revenue opportunities for both companies.